Novo’s cardiovascular and rare disease charge continues
Before the Forma deal Novo brought in assets via Corvidia, Prothena and Heartseed. Some have progressed faster than others.
Ovid takes a novel approach to gene therapy
Ovid and its partner Gensaic have high hopes for a brand-new delivery method, and much to prove.
Better Therapeutics banks on data and partnerships
But difficulties around reimbursement, selling and market value could make it hard for the app maker to live up to its name.
Delfi aims for a cheaper liquid biopsy
With a fresh $225m in the bank, Delfi works towards a cut-price, next-generation lung cancer screen.
Cytokinetics aims to become the Vertex of cardiovascular disease
But a surprise adcom for omecamtiv mecarbil might put a spanner in the works.
To back, or back away from, digital health?
Some medtech venture investors are taken with the promise of digital technologies, while others find them easy to resist.
Asco 2022 – Can Daiichi do it again?
The Japanese drug maker has four more conjugates coming behind Enhertu, and plans to keep future successes to itself.
Sernova gets under the skin
The company believes its new combination technology can make insulin injections a thing of the past.
Thought CETP inhibition was dead? Think again
New Amsterdam wants to prove that the ill-fated mechanism has a role in cardiovascular disease – and this time it’s all about the bad cholesterol.
